Springe direkt zu Inhalt

602d. Chemische Ansätze für synthetische Wirkstofftransportsysteme für systemische Anwendungen

D. Braatz, M. Cherri, M. Tully, M. Dimde, G. Ma, E. Mohammadifar, F. Reisbeck, V. Ahmadi, M. Schirner, R. Haag – 2022

Targeted nanomedicines particularly armed with monoclonal antibodies are considered to be the most promising advanced chemotherapy for malignant cancers; however, their development is hindered by their instability and drug leakage problems. Herein, we constructed a robust cetuximab–polymersome–mertansine nanodrug (C-P-DM1) for highly potent and targeted therapy of epidermal growth factor receptor (EGFR)-positive solid tumors. C-P-DM1 with a tailored cetuximab surface density of 2 per P-DM1 exhibited a size of ca. 60 nm, high stability with minimum DM1 leakage, glutathione-triggered release of native DM1, and 6.0–11.3-fold stronger cytotoxicity in EGFR-positive human breast (MDA-MB-231), lung (A549), and liver (SMMC-7721) cancer cells (IC50 = 27.1–135.5 nM) than P-DM1 control. Notably, intravenous injection of C-P-DM1 effectively repressed subcutaneous MDA-MB-231 breast cancer and orthotopic A549-Luc lung carcinoma in mice without inducing toxic effects. Strikingly, intratumoral injection of C-P-DM1 completely cured 60% of mice bearing breast tumor without recurrence. This robust cetuximab–polymersome–mertansine nanodrug provides a promising new strategy for targeted treatment of EGFR-positive solid malignancies.

Title
602d. Chemische Ansätze für synthetische Wirkstofftransportsysteme für systemische Anwendungen
Author
D. Braatz, M. Cherri, M. Tully, M. Dimde, G. Ma, E. Mohammadifar, F. Reisbeck, V. Ahmadi, M. Schirner, R. Haag
Date
2022
Identifier
DOI: 10.1002/ange.202203942
Source(s)
Citation
Angew. Chem., 2022, e202203942
Type
Text